BRAF and melanoma: Combining the BRAF inhibitor, dabrafenib, with the MEK inhibitor, trametinib, improves progression-free survival in melanoma patients with BRAF V600 mutations [26], and the same combination has demonstrated preliminary benefit in patients with metastatic NSCLC harboring the BRAF V600E mutation [27].